Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity

Journal of Cellular Biochemistry

Volumn 114, Issue 5, 2013, Pages 1135-1144

  Borghese, Cinzia ^a   Cattaruzza, Lara ^a   Pivetta, Eliana ^a   Normanno, Nicola ^b   De Luca, Antonella ^b   Mazzucato, Mario ^a   Celegato, Marta ^a   Colombatti, Alfonso ^a,c   Aldinucci, Donatella ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

CCL5; docetaxel; EGFR; gefitinib; mesenchymal stem cells; prostate cancer; tumor microenvironment

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; RANTES;

ADIPOCYTE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CARCINOMA CELL; CELL AGING; CELL DIFFERENTIATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STEM CELL; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SERUM; SIGNAL TRANSDUCTION; TUMOR PROMOTION;

CELL AGING; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL5; CHEMOTAXIS; CULTURE MEDIA, CONDITIONED; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUBCELLULAR FRACTIONS; TAXOIDS;

EID: 84875127355     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24456     Document Type: Article

References (50)

1. Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, Colombatti A,. 2008. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 122: 769-776.
2. Angelucci A, Gravina GL, Rucci N, Millimaggi D, Festuccia C, Muzi P, Teti A, Vicentini C, Bologna M,. 2006. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 13: 197-210.
3. Angelucci A, Garofalo S, Speca S, Bovadilla A, Gravina GL, Muzi P, Vicentini C, Bologna M,. 2008. Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells. Endocr Relat Cancer 15: 91-100.
4. Bergfeld SA, DeClerck YA,. 2010. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 29: 249-261.
5. Bhattacharya I, Ullrich A,. 2006. Endothelin-1 inhibits adipogenesis: Role of phosphorylation of Akt and ERK1/2. FEBS Lett 580: 5765-5771.
6. Chin SN, Wang L, Moore M, Sridhar SS,. 2010. A review of the patterns of Docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital. Curr Oncol 17: 24-29.
7. Cirri P, Chiarugi P,. 2011. Cancer-associated-fibroblasts and tumour cells: A diabolic liaison driving cancer progression. Cancer Metastasis Rev 31: 195-208.
8. Colombatti M, Grasso S, Porzia A, Fracasso G, Scupoli MT, Cingarlini S, Poffe O, Naim HY, Heine M, Tridente G, Mainiero F, Ramarli D,. 2009. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS ONE 4: e4608.
9. Dayyani F, Gallick GE, Logothetis CJ, Corn PG,. 2011. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 103: 1665-1675.
10. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N,. 2008. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214: 559-567.
11. De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D'Alessio A, De FR, Pinto A, Normanno N,. 2011. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol 226: 2131-2138.
12. DeHaan AM, Wolters NM, Keller ET, Ignatoski KM,. 2009. EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate 69: 528-537.
13. Fritz V, Brondello JM, Gordeladze JO, Reseland JE, Bony C, Yssel H, Noel D, Jorgensen C,. 2011. Bone-metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential. J. Cell Biochem 112: 3234-3245.
14. Gallo M, De Luca A, Lamura L, Normanno N,. 2011. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: Implications for adjuvant therapy of breast cancer. Ann Oncol 23: 597-604.
15. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A,. 2001. Cell communication networks: Epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 20: 1594-1600.
16. Guise T,. 2010. Examining the metastatic niche: Targeting the microenvironment. Semin Oncol 37 (Suppl 2): S2-S14.
17. Gullick WJ,. 2009. The epidermal growth factor system of ligands and receptors in cancer. Eur J Cancer 45 (Suppl 1): 205-210.
18. Houthuijzen JM, Daenen LG, Roodhart JM, Voest EE,. 2012. The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression. Br J Cancer 106: 1901-1906.
19. Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D,. 2010. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 116: 1406-1418.
20. Itahana K, Campisi J, Dimri GP,. 2007. Methods to detect biomarkers of cellular senescence: The senescence-associated beta-galactosidase assay. Methods Mol Biol 371: 21-31.
21. Jin JK, Dayyani F, Gallick GE,. 2011. Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 128: 2545-2561.
22. Karlou M, Tzelepi V, Efstathiou E,. 2010. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol 7: 494-509.
23. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA,. 2007. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563.
24. Krampera M, Pasini A, Rigo A, Scupoli MT, Tecchio C, Malpeli G, Scarpa A, Dazzi F, Pizzolo G, Vinante F,. 2005. HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: Inducing cell expansion and reversibly preventing multilineage differentiation. Blood 106: 59-66.
25. Kuhn NZ, Tuan RS,. 2010. Regulation of stemness and stem cell niche of mesenchymal stem cells: Implications in tumorigenesis and metastasis. J. Cell Physiol 222: 268-277.
26. Le BG, Aubin P, Soliman H, Ropiquet F, Villette JM, Berthon P, Creminon C, Cussenot O, Fiet J,. 1999. Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. Cytokine 11: 157-162.
27. Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E,. 2008. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 123: 2031-2040.
28. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, Keller ET,. 2004. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 21: 399-408.
29. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS,. 2010. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 16: 483-489.
30. Meads MB, Gatenby RA, Dalton WS,. 2009. Environment-mediated drug resistance: A major contributor to minimal residual disease. Nat Rev Cancer 9: 665-674.
31. Morrissey C, Lai JS, Brown LG, Wang YC, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E, Nelson PS, Vessella RL,. 2010. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate 70: 412-424.
32. Normanno N, Gullick WJ,. 2006. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: Different mechanisms of action for a novel therapeutic application? Endocr Relat Cancer 13: 3-6.
33. Normanno N, De Luca A, Aldinucci D, Maiello MR, Mancino M, D'Antonio A, De Filippi R, Pinto A,. 2005. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: Implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer 12: 471-482.
34. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De FG, Caponigro F, Salomon DS,. 2006. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16.
35. Pivetta E, Scapolan M, Wassermann B, Steffan A, Colombatti A, Spessotto P,. 2011. Blood-derived human osteoclast resorption activity is impaired by Hyaluronan-CD44 engagement via a p38-dependent mechanism. J Cell Physiol 226: 769-779.
36. Placencio VR, Li X, Sherrill TP, Fritz G, Bhowmick NA,. 2010. Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth. PLoS ONE 5: e12920.
37. Ponte AL, Marais E, Gallay N, Langonne A, Delorme B, Herault O, Charbord P, Domenech J,. 2007. The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities. Stem Cells 25: 1737-1745.
38. Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M, Pirani P, Florio T, Schettini G,. 2005. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 308: 241-253.
39. Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, Gerritsen MG, Schipper HS, Backer MJ, van AM, Vermaat JS, Moerer P, Ishihara K, Kalkhoven E, Beijnen JH, Derksen PW, Medema RH, Martens AC, Brenkman AB, Voest EE,. 2011. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 20: 370-383.
40. Rosenblatt R, Valdman A, Cheng L, Lopez-Beltran A, Montironi R, Ekman P, Egevad L,. 2009. Endothelin-1 expression in prostate cancer and high grade prostatic intraepithelial neoplasia. Anal Quant Cytol Histol 31: 137-142.
41. Salem HK, Thiemermann C,. 2010. Mesenchymal stromal cells: Current understanding and clinical status. Stem Cells 28: 585-596.
42. Santer FR, Malinowska K, Culig Z, Cavarretta IT,. 2010. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 17: 241-253.
43. Shah K,. 2011. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 64: 739-748.
44. Singh RK, Lokeshwar BL,. 2011. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res 71: 3268-3277.
45. Spessotto P, Lacrima K, Nicolosi PA, Pivetta E, Scapolan M, Perris R,. 2009. Fluorescence-based assays for in vitro analysis of cell adhesion and migration. Methods Mol Biol 522: 221-250.
46. Suva LJ, Washam C, Nicholas RW, Griffin RJ,. 2011. Bone metastasis: Mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7: 208-218.
47. Tang YJ, Sun YH, Xu CL, Wang LH, Gao X, Liu B, Ji JT,. 2011. Prostate cancer cell line PC-3 conditioned medium promotes proliferation and osteogenic differentiation of human bone marrow mesenchymal stem cells. Zhonghua Nan Ke Xue 17: 229-236.
48. Torring N, Jorgensen PE, Sorensen BS, Nexo E,. 2000. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 20: 91-95.
49. Vaday GG, Peehl DM, Kadam PA, Lawrence DM,. 2006. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66: 124-134.
50. Zhang X, Tamasi J, Lu X, Zhu J, Chen H, Tian X, Lee TC, Threadgill DW, Kream BE, Kang Y, Partridge NC, Qin L,. 2011. Epidermal growth factor receptor plays an anabolic role in bone metabolism in vivo. J Bone Miner Res 26: 1022-1034.